AstraZeneca's Priority Review good news provides reprieve

09:40 EDT 2 Aug 2017 | Pharmafile

If there was a company that needed a series of good news stories this week, it was AstraZeneca. The blow of the Mystic trial was enough to have the company seeing stars, and its share value seeing the depths, but it has recovered slightly in the last few days with breakthrough designations, and a Priority Review for its drug, acalabrutinib.

read more

Original Article: AstraZeneca's Priority Review good news provides reprieve


More From BioPortfolio on "AstraZeneca's Priority Review good news provides reprieve"

Quick Search

Relevant Topics

Biotechnology Business
Alliances Astrazeneca Bioethics Boehringer Clinical Research Organization Collaborations GSK Johnson & Johnson Lilly Merck Mergers and Acquisitions Nexium Novartis Pfizer Roche Sanofi ...

Drug Discovery
Clinical Approvals Clinical Trials Drug Approvals Drug Delivery Drug Discovery Generics Drugs Prescription Drugs In the fields of medicine, biotechnology and pharmacology, drug discovery is the process by which drugs are dis...